GPRC5D and BCMA bi-specific CAR-T / Oricell - LARVOL DELTA

GPRC5D and BCMA bi-specific CAR-T: Ex vivo study to simulate early to late-line multiple myeloma (MM) with elevated soluble BCMA. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

GPRC5D and BCMA bi-specific CAR-T: Optimized CAR design to mitigate antigen escape and elicit deep and durable response in heterogeneous multiple myeloma (AACR 2025) - "The pre-clinical data of GPRC5D and BCMA bi-specific CAR-T exhibited superior anti-tumor efficacy and persistence, mitigated Ag escape and preserved potency with shedding BCMA. Our findings provide support for the clinical investigation of the bi-specific CAR-T as a therapeutic approach to broadly and deeply deplete heterogenetic MM cell clones and subsets, potentially leading to durable responses in both newly diagnosed and R/R MM patients."

Heterogeneity • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology